Osmotic device containing venlafaxine and an anti-psychotic agent
AssigneeOsmotica Corp.
InventorsJoaquina Faour, Juan Vergez
Life of this patent
Estimating the term…
Abstract
The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-psychotic agent in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather compression-coated onto the device. The device with spray-coated external core is smaller and easier to swallow than the similar device having a compression-coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.
Claims35
An osmotic device for the delivery of venlafaxine and an anti-psychotic agent comprising:
- a core comprising a therapeutically effective amount of venlafaxine and at least one osmotic agent or osmopolymer;
- a semipermeable membrane surrounding the core and having a passageway there through;
- and
- an external coat comprising a therapeutically effective amount of an anti-psychotic agent;
- wherein the core provides a controlled release of venlafaxine, at least 60% of the venlafaxine is released in a controlled manner within about 12 hours after exposure of the dosage form to an aqueous solution, the external coat provides a rapid release of the anti-psychotic agent, and at least 75% of the anti-psychotic agent is released within about 1 hour after exposure of the dosage form to an aqueous solution.
An osmotic device comprising a first composition comprising a therapeutically effective amount of venlafaxine, and a second composition comprising a therapeutically effective amount of an anti-psychotic agent, wherein the dosage form provides a controlled release of venlafaxine and an immediate release of the anti-psychotic agent;
- at least 60% of the venlafaxine is released in a controlled manner within about 10 hours after exposure of the dosage form to an aqueous solution;
- at least 75% of the anti-psychotic agent is released within about 1 hour after exposure of the dosage form to an aqueous solution;
- and the release of at least one of the venlafaxine and the anti-psychotic agent has a delayed onset.
An osmotic device comprising a first composition comprising a therapeutically effective amount of venlafaxine, and a second composition comprising a therapeutically effective amount of an anti-psychotic agent, wherein the dosage form provides a controlled release of venlafaxine and an immediate release of the anti-psychotic agent;
- at least 60% of the venlafaxine is released in a controlled manner within about 12 hours after exposure of the dosage form to an aqueous solution;
- at least 75% of the anti-psychotic agent is released within about 1 hour after exposure of the dosage form to an aqueous solution.
Dependencies are inferred from the claim text.